China
Africa
Explore chapters and articles related to this topic
Axial Spondyloarthritis
Published in Jason Liebowitz, Philip Seo, David Hellmann, Michael Zeide, Clinical Innovation in Rheumatology, 2023
The current pipeline includes several medications, most notably deucravacitinib, which more specifically target TYK2, potentially with more specific impact on IL23 and interferons.110 Additionally, there is an ongoing phase 2 trial to test namilumab (NCT03622658) and phase 1 study of gimsilumab (NCT04205851), anti-GM-CSF monoclonal antibodies also being investigated for rheumatoid arthritis; data for this mechanism in AxSpA is yet to be published. Additionally, bispecific molecules are being developed for AxSpA (NCT04795141).
Deucravacitinib in the treatment of psoriasis
Published in Journal of Dermatological Treatment, 2023
Tomás Estevinho, Ana Maria Lé, Tiago Torres
In both clinical trials, deucravacitinib proved to be safe and well-tolerated. At week 16, the deucravacitinib group had a slightly lower percentage of patients with adverse events leading to treatment discontinuation than the apremilast and placebo groups (2.4% vs. 5.2% vs. 3.8%, respectively). The most frequently reported adverse events with deucravacitinib were nasopharyngitis and upper respiratory tract infection. Headache, diarrhea, and nausea were also reported, with a similar frequency in the deucravacitinib and placebo groups and a higher frequency in the apremilast group. In terms of laboratory parameters, no significant changes were observed in total cholesterol, creatine phosphokinase, neutrophils, or platelets. No cases of herpes zoster were serious or led to discontinuation, and no cases of opportunistic infections or tuberculosis were reported with deucravacitinib (53,56,57).
New synthetic pharmacotherapeutic approaches to the treatment of moderate-to-severe plaque psoriasis in adults
Published in Expert Opinion on Pharmacotherapy, 2023
Rithi J. Chandy, Sarah G. Bridgeman, Brandon M. Godinich, Steven R. Feldman
Deucravacitinib is a new oral synthetic pharmacotherapeutic treatment for moderate-to-severe plaque psoriasis in adults. Tyrosine kinase 2 (TYK2), a member of the JAK family, is involved in cytokine signaling through mediating intracellular components of adaptive and innate immune responses. TYK2 is therapeutically targeted for plaque psoriasis because of the linkage with the main psoriatic pathogenic pathways – the IL-23/IL-17 axis [45–49]. Deucravacitinib is a TYK2 allosteric inhibitor that binds to an inactive pseudokinase catalyst domain resulting in the inhibition of receptor-mediated stimulation of TYK2 and downstream inactivity which is unlike other TYK2 inhibitors who have competitive enzyme kinetics [12,45,46,50,51]. Deucravacitinib received its first approval in the United States for the treatment of moderate-to-severe plaque psoriasis on September 9th, 2022. The recommended daily dosage is 6 mg administered orally.
TYK2 inhibition: changing the treatment landscape for psoriasis?
Published in Expert Review of Clinical Immunology, 2022
Abrahim Abduelmula, Melinda J. Gooderham
Deucravacitinib showed superior efficacy compared to placebo by 16 weeks of treatment and to placebo and apremilast at week 16 and week 24 for multiple ranked secondary endpoints. The therapeutic effects of deucravacitinib were maintained for 52 weeks[10]. Deucravacitinib was well tolerated and had a safety profile that was consistent with its mechanism of action. Overall, deucravacitinib, a once-daily oral investigational drug, has the potential to become an efficacious and well-tolerated treatment of choice for patients with moderate-to-severe plaque psoriasis.